Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD

Innovent Biologics (IVBXF, 1801.HK) announced a successful Phase 3 STAR study of efdamrofusp alfa (IBI302) in Chinese patients with neovascular age-related macular degeneration, representing a major late-stage clinical milestone. The positive Phase 3 outcome materially de-risks development and enhances commercialization and partnership prospects for the VEGFR/CR1 fusion protein, likely to be viewed favorably by investors. Monitor the company’s forthcoming full data release and regulatory filings to quantify efficacy, safety and potential market opportunity.

Analysis

Innovent Biologics (IVBXF, 1801.HK) announced a successful Phase 3 STAR study of efdamrofusp alfa (IBI302) in Chinese patients with neovascular age-related macular degeneration, representing a major late-stage clinical milestone. The positive Phase 3 outcome materially de-risks development and enhances commercialization and partnership prospects for the VEGFR/CR1 fusion protein, likely to be viewed favorably by investors. Monitor the company’s forthcoming full data release and regulatory filings to quantify efficacy, safety and potential market opportunity.